Stock Track | Illumina Plummets 5.04% as RBC Slashes Price Target to $112

Stock Track2025-04-09

Illumina (ILMN) shares plummeted 5.04% in Tuesday's intraday trading session following a significant price target cut by RBC Capital. The genetic sequencing company's stock faced pressure after RBC lowered its price target from $128 to $112, signaling potential near-term challenges for the firm.

Despite the price target reduction, RBC Capital maintained its Outperform rating on Illumina, suggesting confidence in the company's long-term prospects. This sentiment is echoed by the broader analyst community, as FactSet reports an average rating of overweight for Illumina, with a mean price target of $124.50.

The market's sharp reaction to the price target cut highlights investor sensitivity to changes in analyst outlooks, particularly in the highly competitive and rapidly evolving biotechnology sector. While the immediate stock movement reflects concerns over potential headwinds, the maintained Outperform rating and overall positive analyst sentiment indicate that Illumina's fundamental business outlook remains favorable in the long run.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100489377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-09 03:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100489377","market":"nz","top_or_hot":-1,"title":"Stock Track | Illumina Plummets 5.04% as RBC Slashes Price Target to $112","media":"Stock Track","content":"<p>Illumina (ILMN) shares plummeted 5.04% in Tuesday's intraday trading session following a significant price target cut by RBC Capital. The genetic sequencing company's stock faced pressure after RBC lowered its price target from $128 to $112, signaling potential near-term challenges for the firm.</p>\n\n<p>Despite the price target reduction, RBC Capital maintained its Outperform rating on Illumina, suggesting confidence in the company's long-term prospects. This sentiment is echoed by the broader analyst community, as FactSet reports an average rating of overweight for Illumina, with a mean price target of $124.50.</p>\n\n<p>The market's sharp reaction to the price target cut highlights investor sensitivity to changes in analyst outlooks, particularly in the highly competitive and rapidly evolving biotechnology sector. While the immediate stock movement reflects concerns over potential headwinds, the maintained Outperform rating and overall positive analyst sentiment indicate that Illumina's fundamental business outlook remains favorable in the long run.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Illumina Plummets 5.04% as RBC Slashes Price Target to $112</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Illumina Plummets 5.04% as RBC Slashes Price Target to $112\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-09 03:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Illumina (ILMN) shares plummeted 5.04% in Tuesday's intraday trading session following a significant price target cut by RBC Capital. The genetic sequencing company's stock faced pressure after RBC lowered its price target from $128 to $112, signaling potential near-term challenges for the firm.</p>\n\n<p>Despite the price target reduction, RBC Capital maintained its Outperform rating on Illumina, suggesting confidence in the company's long-term prospects. This sentiment is echoed by the broader analyst community, as FactSet reports an average rating of overweight for Illumina, with a mean price target of $124.50.</p>\n\n<p>The market's sharp reaction to the price target cut highlights investor sensitivity to changes in analyst outlooks, particularly in the highly competitive and rapidly evolving biotechnology sector. While the immediate stock movement reflects concerns over potential headwinds, the maintained Outperform rating and overall positive analyst sentiment indicate that Illumina's fundamental business outlook remains favorable in the long run.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1100489377","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100489377","pubTimestamp":1744141011,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Illumina  shares plummeted 5.04% in Tuesday's intraday trading session following a significant price target cut by RBC Capital. The genetic sequencing company's stock faced pressure after RBC lowered its price target from $128 to $112, signaling potential near-term challenges for the firm.Despite the price target reduction, RBC Capital maintained its Outperform rating on Illumina, suggesting confidence in the company's long-term prospects. This sentiment is echoed by the broader analyst communit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"加拿大皇家银行(RBC)将目标价下调至112美元，Illumina股价暴跌5.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"Illumina (ILMN) shares plummeted 5.04% in Tuesday's intraday trading session following a significant price target cut by RBC Capital. The genetic sequencing company's stock faced pressure after RBC lowered its price target from $128 to $112, signaling potential near-term challenges for the firm.\nDespite the price target reduction, RBC Capital maintained its Outperform rating on Illumina, suggesting confidence in the company's long-term prospects. This sentiment is echoed by the broader analyst community, as FactSet reports an average rating of overweight for Illumina, with a mean price target of $124.50.\nThe market's sharp reaction to the price target cut highlights investor sensitivity to changes in analyst outlooks, particularly in the highly competitive and rapidly evolving biotechnology sector. While the immediate stock movement reflects concerns over potential headwinds, the maintained Outperform rating and overall positive analyst sentiment indicate that Illumina's fundamental business outlook remains favorable in the long run.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100489377","isCrawlerRequest":true}